VNRX Insider Trading

Insider Ownership Percentage: 12.80%
Insider Buying (Last 12 Months): $152,200.00
Insider Selling (Last 12 Months): $33,000.00

VolitionRx Insider Trading History Chart

This chart shows the insider buying and selling history at VolitionRx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

VolitionRx Share Price & Price History

Current Price: $0.79
Price Change: Price Decrease of -0.02 (-2.46%)
As of 11/22/2024 01:00 AM ET

This chart shows the closing price history over time for VNRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

VolitionRx Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/20/2024Guy Archibald InnesDirectorBuy150,000$0.67$100,500.00406,683View SEC Filing Icon  
1/2/2024Corp Ltd EightMajor ShareholderSell20,000$0.90$18,000.00298,419View SEC Filing Icon  
12/18/2023Salvatore Thomas ButeraCEOBuy10,000$0.83$8,300.0099,350View SEC Filing Icon  
12/15/2023Corp Ltd EightMajor ShareholderSell20,000$0.75$15,000.00318,419View SEC Filing Icon  
12/15/2023Salvatore Thomas ButeraCEOBuy10,000$0.77$7,700.0089,350View SEC Filing Icon  
12/13/2023Rodney Gerard RootsaertInsiderBuy10,000$0.60$6,000.0078,652View SEC Filing Icon  
12/8/2023Cameron John ReynoldsCEOBuy10,000$0.67$6,700.001,704,518View SEC Filing Icon  
11/27/2023Guy Archibald InnesDirectorBuy20,000$0.77$15,400.00627,161View SEC Filing Icon  
11/24/2023Guy Archibald InnesDirectorBuy10,000$0.76$7,600.00607,161View SEC Filing Icon  
11/22/2023Guy Archibald InnesDirectorBuy20,000$0.71$14,200.00597,161View SEC Filing Icon  
11/16/2023Salvatore Thomas ButeraCEOBuy10,000$0.81$8,100.0079,350View SEC Filing Icon  
9/5/2023Phillip BarnesDirectorBuy5,000$1.30$6,500.0024,686View SEC Filing Icon  
8/31/2023Martin Charles FaulkesDirectorBuy9,716$1.28$12,436.481,673,532View SEC Filing Icon  
8/29/2023Jacob Vincent MicallefInsiderBuy11,250$1.24$13,950.0046,250View SEC Filing Icon  
8/25/2023Jacob Vincent MicallefInsiderBuy20,000$1.24$24,800.00235,140View SEC Filing Icon  
8/24/2023Gaetan MichelCOOBuy5,000$1.23$6,150.00212,997View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for VolitionRx (NYSE:VNRX)

8.09% of VolitionRx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

VolitionRx Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024Geode Capital Management LLC730,448$0.44M0.0%+15.1%0.788%Search for SEC Filing on Google Icon
10/29/2024Ground Swell Capital LLC45,959$28K0.0%+78.8%0.050%Search for SEC Filing on Google Icon
1/17/2024Silverberg Bernstein Capital Management LLC147,038$0.11M0.1%N/A0.187%Search for SEC Filing on Google Icon
11/14/2023Lagoda Investment Management L.P.3,882,850$2.68M1.8%-1.2%4.969%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
VolitionRx logo
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Read More on VolitionRx

Today's Range

Now: $0.79
Low: $0.77
High: $0.84

50 Day Range

MA: $0.69
Low: $0.55
High: $0.88

52 Week Range

Now: $0.79
Low: $0.43
High: $1.23

Volume

57,920 shs

Average Volume

160,267 shs

Market Capitalization

$73.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Who are the company insiders with the largest holdings of VolitionRx?

VolitionRx's top insider investors include:
  1. Cameron John Reynolds (CEO)
  2. Martin Charles Faulkes (Director)
  3. Guy Archibald Innes (Director)
  4. Corp Ltd Eight (Major Shareholder)
  5. Jacob Vincent Micallef (Insider)
  6. Gaetan Michel (COO)
  7. Salvatore Thomas Butera (CEO)
  8. Rodney Gerard Rootsaert (Insider)
  9. Phillip Barnes (Director)
Learn More about top insider investors at VolitionRx.

Who are the major institutional investors of VolitionRx?

VolitionRx's top institutional investors include:
  1. Geode Capital Management LLC — 0.79%
  2. Ground Swell Capital LLC — 0.05%
Learn More about top institutional investors of VolitionRx stock.

Which institutional investors are buying VolitionRx stock?

During the last quarter, VNRX stock was acquired by institutional investors including:
  1. Geode Capital Management LLC
  2. Ground Swell Capital LLC
Within the previous year, these company insiders have bought VolitionRx stock:
  1. Cameron John Reynolds (CEO)
  2. Martin Charles Faulkes (Director)
  3. Guy Archibald Innes (Director)
  4. Corp Ltd Eight (Major Shareholder)
  5. Jacob Vincent Micallef (Insider)
  6. Gaetan Michel (COO)
  7. Salvatore Thomas Butera (CEO)
  8. Rodney Gerard Rootsaert (Insider)
Learn More investors buying VolitionRx stock.